Literature DB >> 7542559

Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

L B Owen-Schaub1, L S Angelo, R Radinsky, C F Ware, T G Gesner, D P Bartos.   

Abstract

Fas/APO-1, a member of the NGF/TNF receptor superfamily expressed on the cell-surface of normal and malignant cells, is known to induce cell death by apoptosis. In the present study, we have investigated Fas/APO-1 gene defects in a human osteosarcoma cell line resistant to the apoptosis-inducing effects of anti-Fas. cDNA cloning and sequencing revealed that these cells contained both 'authentic' and mutant Fas/APO-1 containing a 63 base pair in-frame deletion spanning the transmembrane domain, designated DFas/APO-1. Direct evidence for the existence of a soluble Fas/APO-1 protein was obtained by immunoprecipitation and Western blotting. Taken together with prior studies demonstrating a role for Fas/APO-1 and Fas ligand, respectively, in tumor target cell killing by cytotoxic T-lymphocytes, production of soluble Fas/APO-1 might have significant implications in malignant disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542559     DOI: 10.1016/0304-3835(95)03834-j

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

Review 1.  Is bone a target-tissue for the nervous system? New advances on the understanding of their interactions.

Authors:  J M García-Castellano; P Díaz-Herrera; J A Morcuende
Journal:  Iowa Orthop J       Date:  2000

2.  Markers of degeneration and regeneration in Duchenne muscular dystrophy.

Authors:  E Abdel-Salam; I Abdel-Meguid; S S Korraa
Journal:  Acta Myol       Date:  2009-12

Review 3.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas.

Authors:  Y Nambu; S J Hughes; A Rehemtulla; D Hamstra; M B Orringer; D G Beer
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

5.  Systemic immune response after laparoscopic and open cholecystectomy.

Authors:  Shyr-Ming Sheen-Chen; Han-Shiang Chen; Hock-Liew Eng; Wei-Jen Chen; Bruno Jawan
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

6.  Soluble CD95 (Fas/APO-1) in malignant glioma: (no) implications for CD95-based immunotherapy?

Authors:  J R Streffer; M Schuster; F Zipp; M Weller
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

7.  In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation.

Authors:  Susan Erster; Motohiro Mihara; Roger H Kim; Oleksi Petrenko; Ute M Moll
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

8.  Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El Bassiouny; Nora E I El-Bassiouni; Mona M F Nosseir; Mona M K Zoheiry; Eman G El-Ahwany; Faten Salah; Zeinab S O Omran; Raafat A Ibrahim
Journal:  Medscape J Med       Date:  2008-06-03

9.  Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.

Authors:  S Jodo; S Kobayashi; Y Nakajima; T Matsunaga; N Nakayama; N Ogura; N Kayagaki; K Okumura; T Koike
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

10.  Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.

Authors:  Koji Yamanegi; Junko Yamane; Masaki Hata; Hideki Ohyama; Naoko Yamada; Nahoko Kato-Kogoe; Hiroyuki Futani; Keiji Nakasho; Haruki Okamura; Nobuyuki Terada
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.